185 related articles for article (PubMed ID: 23660814)
21. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
22. The inhibitory activity of HL-7 and HL-10 peptide from scorpion venom (Hemiscorpius lepturus) on angiotensin converting enzyme: Kinetic and docking study.
Setayesh-Mehr Z; Asoodeh A
Bioorg Chem; 2017 Dec; 75():30-37. PubMed ID: 28910674
[TBL] [Abstract][Full Text] [Related]
23. Validated ligand mapping of ACE active site.
Kuster DJ; Marshall GR
J Comput Aided Mol Des; 2005 Aug; 19(8):609-15. PubMed ID: 16307311
[TBL] [Abstract][Full Text] [Related]
24. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain.
Georgiadis D; Cuniasse P; Cotton J; Yiotakis A; Dive V
Biochemistry; 2004 Jun; 43(25):8048-54. PubMed ID: 15209500
[TBL] [Abstract][Full Text] [Related]
25. Structural constraints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme.
Perich RB; Jackson B; Johnston CI
Eur J Pharmacol; 1994 Feb; 266(3):201-11. PubMed ID: 8174603
[TBL] [Abstract][Full Text] [Related]
26. Insights into the molecular interactions between aminopeptidase and amyloid beta peptide using molecular modeling techniques.
Dhanavade MJ; Sonawane KD
Amino Acids; 2014 Aug; 46(8):1853-66. PubMed ID: 24729013
[TBL] [Abstract][Full Text] [Related]
27. Structure of angiotensin I-converting enzyme.
Sturrock ED; Natesh R; van Rooyen JM; Acharya KR
Cell Mol Life Sci; 2004 Nov; 61(21):2677-86. PubMed ID: 15549168
[TBL] [Abstract][Full Text] [Related]
28. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Toropygin IY; Kugaevskaya EV; Mirgorodskaya OA; Elisseeva YE; Kozmin YP; Popov IA; Nikolaev EN; Makarov AA; Kozin SA
Rapid Commun Mass Spectrom; 2008; 22(2):231-9. PubMed ID: 18085519
[TBL] [Abstract][Full Text] [Related]
29. Structural significance of Neprylysin from Streptococcus suis GZ1 in the degradation of Aβ peptides, a causative agent in Alzheimer's disease.
Kamble S; Barale S; Dhanavade M; Sonawane K
Comput Biol Med; 2021 Sep; 136():104691. PubMed ID: 34343891
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme.
Zhou M; Du K; Ji P; Feng W
Biophys Chem; 2012 Jul; 168-169():60-6. PubMed ID: 22835627
[TBL] [Abstract][Full Text] [Related]
31. Surface plasmon resonance analysis of the binding mechanism of pharmacological and peptidic inhibitors to human somatic angiotensin I-converting enzyme.
Zidane F; Zeder-Lutz G; Altschuh D; Girardet JM; Miclo L; Corbier C; Cakir-Kiefer C
Biochemistry; 2013 Dec; 52(48):8722-31. PubMed ID: 24168709
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin Converting Enzyme (ACE)-Peptide Interactions: Inhibition Kinetics, In Silico Molecular Docking and Stability Study of Three Novel Peptides Generated from Palm Kernel Cake Proteins.
Zarei M; Abidin NBZ; Auwal SM; Chay SY; Haiyee ZA; Sikin AM; Saari N
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31590308
[TBL] [Abstract][Full Text] [Related]
33. Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril.
Akif M; Masuyer G; Schwager SL; Bhuyan BJ; Mugesh G; Isaac RE; Sturrock ED; Acharya KR
FEBS J; 2011 Oct; 278(19):3644-50. PubMed ID: 21810173
[TBL] [Abstract][Full Text] [Related]
34. Structural and molecular bases of angiotensin-converting enzyme inhibition by bovine casein-derived peptides: an
De Oliveira TV; Guimarães AP; Bressan GC; Maia ER; Coimbra JSDR; Polêto MD; De Oliveira EB
J Biomol Struct Dyn; 2021 Mar; 39(4):1386-1403. PubMed ID: 32066337
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta ); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity.
Hu J; Igarashi A; Kamata M; Nakagawa H
J Biol Chem; 2001 Dec; 276(51):47863-8. PubMed ID: 11604391
[TBL] [Abstract][Full Text] [Related]
36. Angiotensin I-converting enzyme transition state stabilization by HIS1089: evidence for a catalytic mechanism distinct from other gluzincin metalloproteinases.
Fernandez M; Liu X; Wouters MA; Heyberger S; Husain A
J Biol Chem; 2001 Feb; 276(7):4998-5004. PubMed ID: 11067854
[TBL] [Abstract][Full Text] [Related]
37. Structural features of angiotensin-I converting enzyme catalytic sites: conformational studies in solution, homology models and comparison with other zinc metallopeptidases.
Spyroulias GA; Galanis AS; Pairas G; Manessi-Zoupa E; Cordopatis P
Curr Top Med Chem; 2004; 4(4):403-29. PubMed ID: 14965309
[TBL] [Abstract][Full Text] [Related]
38. [Study of substrate specificity of a new peptide substrate of endothelin converting enzyme].
Gureeva TA; Kugaevskaia EV; Pozdnev VF; Prozorovskiĭ VN; Eliseeva IuE; Solov'eva NI
Biomed Khim; 2007; 53(2):172-80. PubMed ID: 17639718
[TBL] [Abstract][Full Text] [Related]
39. Dual effects of familial Alzheimer's disease mutations (D7H, D7N, and H6R) on amyloid β peptide: correlation dynamics and zinc binding.
Xu L; Chen Y; Wang X
Proteins; 2014 Dec; 82(12):3286-97. PubMed ID: 25137638
[TBL] [Abstract][Full Text] [Related]
40. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme.
Natesh R; Schwager SL; Evans HR; Sturrock ED; Acharya KR
Biochemistry; 2004 Jul; 43(27):8718-24. PubMed ID: 15236580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
